[go: up one dir, main page]

PE20030069A1 - Composicion de liberacion sostenida y proceso para producirla - Google Patents

Composicion de liberacion sostenida y proceso para producirla

Info

Publication number
PE20030069A1
PE20030069A1 PE2002000577A PE2002000577A PE20030069A1 PE 20030069 A1 PE20030069 A1 PE 20030069A1 PE 2002000577 A PE2002000577 A PE 2002000577A PE 2002000577 A PE2002000577 A PE 2002000577A PE 20030069 A1 PE20030069 A1 PE 20030069A1
Authority
PE
Peru
Prior art keywords
molecular weight
produce
composition
sustained release
pro
Prior art date
Application number
PE2002000577A
Other languages
English (en)
Inventor
Kazumichi Yamamoto
Akiko Yamada
Yoshio Hata
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26617908&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20030069(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of PE20030069A1 publication Critical patent/PE20030069A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • A61K38/09Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1641Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647Polyesters, e.g. poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

COMPOSICION QUE COMPRENDE: 1)UN POLIMERO DE ACIDO LACTICO-ACIDO GLICOLICO, QUE TIENE UNA RELACION DE PESO MOLECULAR MEDIO, EN PESO A PESO MOLECULAR MEDIO EN NUMERO DE APROXIMADAMENTE 1,90 O MENOS, O UNA SAL DEL MISMO; Y, 2)UNA SUSTANCIA FISIOLOGICAMENTE ACTIVA QUE ES UN PEPTIDO FISIOLOGICAMENTE ACTIVO O UN DERIVADO DE LH-RH QUE ES UN PEPTIDO REPRESENTADO POR LA FORMULA 5-OXO-PRO-HIS-TRP-SER-TYR-Y-LEU-ARG-PRO-Z, SIENDO Y: DLEU, DALA, DTRP, DSER (TBU), D2NAL O DHIS (IMBZL), Y Z SIGNIFICA HH, C2H5 O GLY-NH2, O UNA SAL DEL MISMO. DONDE, EL PESO MOLECULAR DE (1) ES DE 3 000 A 100 000
PE2002000577A 2001-06-29 2002-06-27 Composicion de liberacion sostenida y proceso para producirla PE20030069A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001199462 2001-06-29
JP2001340980 2001-11-06

Publications (1)

Publication Number Publication Date
PE20030069A1 true PE20030069A1 (es) 2003-03-17

Family

ID=26617908

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002000577A PE20030069A1 (es) 2001-06-29 2002-06-27 Composicion de liberacion sostenida y proceso para producirla

Country Status (31)

Country Link
US (3) US20040241229A1 (es)
EP (2) EP1399133B2 (es)
JP (3) JP5491318B2 (es)
KR (3) KR100988178B1 (es)
CN (1) CN1535141B (es)
AR (1) AR034640A1 (es)
AT (1) ATE429903T1 (es)
AU (1) AU2002311630B2 (es)
BR (1) BR0210572A (es)
CA (1) CA2451718C (es)
CO (1) CO5540368A2 (es)
CY (1) CY1109272T1 (es)
CZ (1) CZ306388B6 (es)
DE (1) DE60232147D1 (es)
DK (1) DK1399133T4 (es)
ES (1) ES2324156T5 (es)
HU (1) HU230152B1 (es)
IL (1) IL159060A0 (es)
MX (1) MXPA03011440A (es)
MY (1) MY139606A (es)
NO (1) NO333531B1 (es)
NZ (1) NZ529968A (es)
PE (1) PE20030069A1 (es)
PL (1) PL212531B1 (es)
PT (1) PT1399133E (es)
RU (2) RU2297240C2 (es)
SI (1) SI1399133T2 (es)
SK (1) SK287568B6 (es)
TW (1) TWI225416B (es)
WO (1) WO2003002091A2 (es)
ZA (1) ZA200309153B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2490351C (en) * 2002-06-25 2011-11-01 Takeda Pharmaceutical Company Limited Process for producing sustained-release composition
KR100684682B1 (ko) * 2002-09-24 2007-02-22 아사히 가세이 케미칼즈 가부시키가이샤 글리콜산 공중합체 및 그의 제조 방법
TW200529890A (en) * 2004-02-10 2005-09-16 Takeda Pharmaceutical Sustained-release preparations
TW200613012A (en) * 2004-07-02 2006-05-01 Takeda Pharmaceuticals Co Sustained-release composition, process for producing the same and use of the same
DE602006000381T2 (de) * 2005-04-28 2008-12-18 Nipro Corp., Osaka Bioabsorbierbare pharmazeutische Zusammensetzung enthaltend einen PLGA-Copolymer
MX2008009125A (es) 2006-01-18 2008-10-23 Qps Llc Composiciones farmaceuticas con estabilidad mejorada.
JP4564098B2 (ja) 2006-12-18 2010-10-20 武田薬品工業株式会社 徐放性組成物およびその製造法
CA2678350C (en) 2007-02-15 2015-11-17 Qlt Usa, Inc. Low-burst poly(lactide-glycolide)
KR101008462B1 (ko) * 2007-07-26 2011-01-14 조남열 치어류 이동용 어도 장치
KR100969641B1 (ko) * 2007-11-12 2010-07-14 민선영 저수지의 제방용 어도
KR100969642B1 (ko) * 2007-11-15 2010-07-12 민선영 하천의 보용 어도
US8641900B2 (en) 2009-11-05 2014-02-04 Taiwan Biotech Co., Ltd Method and device for continuously preparing microspheres, and collection unit thereof
TWI477266B (zh) * 2009-11-05 2015-03-21 Taiwan Biotech Co Ltd 連續製備微粒的方法、裝置及其收集單元
EP2697361A1 (en) * 2011-04-11 2014-02-19 Cellcura Asa Protein-free culture media products for manufacturing viral-based vaccines
US9517210B2 (en) 2012-07-12 2016-12-13 Takeda Pharmaceutical Company Limited Method for producing microcapsule powder
RU2572992C2 (ru) * 2012-08-28 2016-01-20 Федеральное государственное бюджетное образовательное учреждение высшего образования "Курская государственная сельскохозяйственная академия имени И.И. Иванова" Способ получения микрокапсул водорастворимых препаратов пестицидов
EP2985304B1 (en) 2013-04-11 2024-08-14 Mitsui Chemicals, Inc. Method for manufacturing lactic acid-glycolic acid copolymer and method for manufacturing salt thereof
RU2537248C1 (ru) * 2013-05-24 2014-12-27 Екатерина Евгеньевна Быковская Способ получения микрокапсул гетероциклических соединений триазинового ряда
RU2537173C1 (ru) * 2013-05-24 2014-12-27 Александр Александрович Кролевец Способ получения микрокапсул гетероциклических соединений триазинового ряда
JP6564369B2 (ja) 2013-12-09 2019-08-21 デュレクト コーポレイション 薬学的活性剤複合体、ポリマー複合体、ならびにこれらを伴う組成物及び方法
US9956164B2 (en) 2014-04-16 2018-05-01 Veyx-Pharma Gmbh Veterinary pharmaceutical composition and use thereof
AR101476A1 (es) 2014-08-07 2016-12-21 Acerta Pharma Bv Métodos para tratar cánceres, enfermedades inmunes y autoinmunes, y enfermedades inflamatorias en base a la tasa de ocupación de la tirosin quinasa de bruton (btk) y a la tasa de resíntesis de la tirosin quinasa de bruton (btk)
CN104224731A (zh) * 2014-09-11 2014-12-24 北京天晟泰丰医药科技有限公司 一种不含致敏性辅料的九肽微球的制备方法
JP5938762B1 (ja) * 2015-09-01 2016-06-22 日揮株式会社 マイクロカプセル製剤及びその製造方法
CN110856690B (zh) * 2018-08-22 2024-07-02 深圳善康医药科技股份有限公司 一种植入剂包膜及干燥装置
WO2021234731A1 (en) * 2020-05-18 2021-11-25 Dr Reddy's Institute Of Life Sciences Sustained release compositions

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
CA1236641A (en) 1984-07-06 1988-05-10 Motoaki Tanaka Copolymer of lactic acid and glycolic acid and method for producing same
JPH0678425B2 (ja) 1984-07-06 1994-10-05 和光純薬工業株式会社 重合体の新規製造法
JPH0720859B2 (ja) 1985-02-07 1995-03-08 武田薬品工業株式会社 マイクロカプセルの製造法
DE3678308D1 (de) 1985-02-07 1991-05-02 Takeda Chemical Industries Ltd Verfahren zur herstellung von mikrokapseln.
JP2551756B2 (ja) 1985-05-07 1996-11-06 武田薬品工業株式会社 ポリオキシカルボン酸エステルおよびその製造法
EP0328089A3 (en) 1988-02-10 1990-11-28 Abbott Laboratories Reduced size lhrh analogs
US5110904A (en) 1989-08-07 1992-05-05 Abbott Laboratories Lhrh analogs
JP2653255B2 (ja) * 1990-02-13 1997-09-17 武田薬品工業株式会社 長期徐放型マイクロカプセル
ATE168391T1 (de) 1990-04-13 1998-08-15 Takeda Chemical Industries Ltd Biologisch abbaubare hochmolekulare polymere, ihre herstellung und ihre verwendung
JP3200706B2 (ja) 1990-04-13 2001-08-20 武田薬品工業株式会社 生体内分解型高分子重合物
EP0535937B2 (en) * 1991-10-01 2008-05-21 Takeda Chemical Industries, Ltd. Prolonged release microparticle preparation and production of the same
JP3277342B2 (ja) 1992-09-02 2002-04-22 武田薬品工業株式会社 徐放性マイクロカプセルの製造法
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
JP3761594B2 (ja) * 1993-07-05 2006-03-29 武田薬品工業株式会社 徐放性製剤の製造法
NZ260909A (en) * 1993-07-05 1995-04-27 Takeda Chemical Industries Ltd Production of sustained release preparation by allowing a water-soluble polypeptide to permeate into a biodegradable matrix in an aqueous solution
JPH08259460A (ja) 1995-01-23 1996-10-08 Takeda Chem Ind Ltd 徐放性製剤の製造法
CA2192782C (en) * 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
JPH11269094A (ja) 1998-01-16 1999-10-05 Takeda Chem Ind Ltd 徐放性組成物、その製造法および用途
US6740634B1 (en) * 1998-01-16 2004-05-25 Takeda Chemical Industries, Ltd. Sustained release compositions, process for producing the same and utilization thereof
WO2000035990A1 (fr) * 1998-12-15 2000-06-22 Takeda Chemical Industries, Ltd. Procede de production d'un polymere
JP3716146B2 (ja) * 1998-12-15 2005-11-16 武田薬品工業株式会社 ポリマーの製造方法
JP2002114667A (ja) 2000-10-11 2002-04-16 Ltt Institute Co Ltd 徐放性製剤用組成物、その製造法および徐放性マイクロカプセル製剤
TW200526267A (en) * 2001-06-29 2005-08-16 Takeda Chemical Industries Ltd Controlled release composition and method of producing the same
CA2490351C (en) * 2002-06-25 2011-11-01 Takeda Pharmaceutical Company Limited Process for producing sustained-release composition

Also Published As

Publication number Publication date
JP2012136530A (ja) 2012-07-19
ZA200309153B (en) 2005-01-26
RU2004102503A (ru) 2005-03-10
US8258252B2 (en) 2012-09-04
EP1399133B1 (en) 2009-04-29
DK1399133T4 (da) 2012-07-23
HK1061802A1 (en) 2004-10-08
AR034640A1 (es) 2004-03-03
HU230152B1 (hu) 2015-09-28
BR0210572A (pt) 2004-08-03
ES2324156T3 (es) 2009-07-31
WO2003002091A3 (en) 2003-07-24
HUP0400382A2 (hu) 2004-12-28
US20040241229A1 (en) 2004-12-02
MXPA03011440A (es) 2004-07-01
PL367491A1 (en) 2005-02-21
CO5540368A2 (es) 2005-07-29
IL159060A0 (en) 2004-05-12
SK287568B6 (sk) 2011-02-04
CA2451718A1 (en) 2003-01-09
JP5931147B2 (ja) 2016-06-08
JP2015007120A (ja) 2015-01-15
EP1399133B2 (en) 2012-05-02
MY139606A (en) 2009-10-30
US20120295848A1 (en) 2012-11-22
DE60232147D1 (de) 2009-06-10
KR20040018401A (ko) 2004-03-03
CY1109272T1 (el) 2014-07-02
NO333531B1 (no) 2013-07-01
ES2324156T5 (es) 2012-07-23
HUP0400382A3 (en) 2010-01-28
EP2108363A1 (en) 2009-10-14
ATE429903T1 (de) 2009-05-15
SK15612003A3 (sk) 2004-07-07
RU2006143104A (ru) 2008-06-20
SI1399133T1 (sl) 2009-10-31
EP1399133A2 (en) 2004-03-24
KR20090108640A (ko) 2009-10-15
TWI225416B (en) 2004-12-21
CN1535141A (zh) 2004-10-06
PL212531B1 (pl) 2012-10-31
RU2434644C2 (ru) 2011-11-27
NO20035737L (no) 2004-02-20
CZ306388B6 (cs) 2017-01-04
SI1399133T2 (sl) 2012-08-31
AU2002311630B2 (en) 2007-07-19
DK1399133T3 (da) 2009-08-03
RU2297240C2 (ru) 2007-04-20
CZ20033492A3 (cs) 2005-01-12
CN1535141B (zh) 2013-04-24
CA2451718C (en) 2011-03-15
JP5860300B2 (ja) 2016-02-16
KR100988178B1 (ko) 2010-10-18
US20080108778A1 (en) 2008-05-08
JP2010280703A (ja) 2010-12-16
WO2003002091A2 (en) 2003-01-09
JP5491318B2 (ja) 2014-05-14
PT1399133E (pt) 2009-06-05
NO20035737D0 (no) 2003-12-19
NZ529968A (en) 2005-08-26
KR20090096755A (ko) 2009-09-14

Similar Documents

Publication Publication Date Title
PE20030069A1 (es) Composicion de liberacion sostenida y proceso para producirla
AR098261A2 (es) Composición de liberación controlada y método para producirla
CY1107051T1 (el) Αντι-διηθητικα και αντι-αγγειογενετικα θραυσματα ουροκινασης και η χρηση τους
CY1119723T1 (el) Φαρμακοτεχνικες μορφες πεπτιδιου περιεχουσες προπυλενογλυκολη οι οποιες ειναι βελτιστες για παραγωγη και για χρηση σε συσκευες ενεσεων
PE20081842A1 (es) Composicion de liberacion sostenida y metodos para producirlas
JP2003206240A5 (es)
AR045937A1 (es) Modulacion de la expresion del factor de iniciacion eucariotico eif4e
BR0208183A (pt) Peptìdeo modificado por wt1
NO974270L (no) Insulinderivater
MX2011011960A (es) Peptidos penetradores de celulas.
CY1108656T1 (el) Παραγωγα της πυριμιδινο-2,4-διονης ως ανταγωνιστες των υποδοχεων της εκλυουσας γοναδοτροπινες ορμονης
ATE446758T1 (de) Verwendung von wachstumshormonsekretagoga zur förderung der beweglichkeit des verdauungstrakts
CY1107668T1 (el) Χρηση αμινοξικων αντισπασμωδικων για τη θεραπευτικη αγωγη του πονου
BR0313424A (pt) Forma de dosagem e processo para a preparação de uma forma de dosagem
AR051778A2 (es) Derivados del acido dimetilaminocrotonico y procesos para supreparacion
PE20020802A1 (es) COMPUESTO DE LACTAMA COMO INHIBIDOR DE LA LIBERACION DEL PEPTIDO ß-AMILOIDE
JP5982562B2 (ja) ペプチドの塩酸塩及び他のペプチドとの併用によるその免疫治療用途
NO20043115L (no) Substituerte diketopiperaziner som oksytocin antagonister
EP1184035A3 (en) Use of growth hormone secretagogues for treatment of physical performance decline
CA2471521A1 (en) Novel microsphere and method for production thereof
ATE205219T1 (de) Ein verbessertes peptid, immunogene zusammensetzung und impfstoff oder medizinische präparate, eine methode zur immunisierung von tieren gegen das hormon lhrh und analoge des lhrh-tendem-repeat-peptid und deren verwendung als impfstoff
US5491217A (en) LHRH antagonists having modified aminoacyl residues at positions 5 and 6
AR015962A1 (es) LANTIBIoTICO RELACIONADO CON ACTAGARDINA, PROCEDIMIENTO PARA SU PREPARACIoN, MEDICAMENTO, PROCEDIMIENTO PARA LA PREPARACIoN DE UN MEDICAMENTO Y EMPLEO DEL MISMO PARA LA PREPARACIoN DE UN MEDICAMENTO PARA ENFERMEDADES INFECCIOSAS BACTERIANAS.
ECSP099029A (es) Nuevos análogos del péptido intestinal vasoactivo
AR054340A1 (es) Composiciones para el tratamiento del cabello

Legal Events

Date Code Title Description
FC Refusal